Sydvestjysk Sygehus

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease3 trials
• Atrial fibrillation2 trials
• COPD2 trials
• Crohn's disease2 trials
• Obesity2 trials
• Stroke2 trials
• Type 1 diabetes2 trials
• Asthma1 trial
• Chronic lymphocytic leukaemia1 trial
• Chronic rhinosinusitis with nasal polyps1 trial
• Colorectal cancer1 trial
• Coronary artery disease1 trial
• and 10 more

Phase

• Phase 310 trials
• Phase 46 trials
• Phase 23 trials

Status

• Completed11 trials
• Active, not recruiting5 trials
• Recruiting4 trials
• Terminated1 trial

Lead sponsor

• Janssen Research & Development, LLC2 trials
• Odense University Hospital2 trials
• Aarhus University Hospital1 trial
• Amgen1 trial
• AstraZeneca1 trial
• and 14 more

Running trials

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

  NCT06700343· Phase 3· Amgen· Source

• Recruiting

  Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease

  NCT06923709· Phase 2· Odense University Hospital· Source

• Recruiting

  New treatments to reduce cardiovascular disease in type 1 diabetes

  2023-505794-32-04· Phase 3· Steno Diabetes Center Copenhagen· Source

• Active, not recruiting

  Screening and intervention for subclinical coronary artery disease in patients with type 2 diabetes: THE STENO INTEN-CT STUDY

  2022-500143-21-01· Phase 4· Aarhus University Hospital· Source

• Active, not recruiting

  A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

  NCT05197049· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

  NCT04608318· Phase 3· German CLL Study Group· Source

• Recruiting

  A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

  NCT04332822· Phase 3· Nordic Lymphoma Group· Source

• Recruiting

  The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis

  NCT03862859· Phase 4· Nicholas Carlson· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease2 recruiting
• Atrial fibrillation1 recruiting
• Crohn's disease1 recruiting
• Stroke1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

  NCT05901831· Phase 3· Bayer· Source

• Active, not recruiting

  A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps

  NCT05942222· Phase 4· Copenhagen University Hospital, Rigshospitalet· Source

• Completed

  Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

  NCT05767034· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  MORPHINE PHARMACOKINETICS AND –DYNAMICS IN HEALTHY VOLUNTEERS AND PATIENTS WITH OBESITY AND OBSTRUCTIVE SLEEP APNOEA. AN INVESTIGATOR INITIATED, CLINICAL STUDY OF THE IMPACT OF OBESITY AND SLEEP APNOEA ON THE PHARMACOLOGY OF MORPHINE

  2022-500779-29-00· Phase 2· Sydvestjysk Sygehus· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  A Study in Participants With Non-cirrhotic NASH With Fibrosis

  NCT05638737· Phase 2· AstraZeneca· Source

• Completed

  A Study of Population and Sex-specific Troponin Cutoffs for Ruling Out Acute Myocardial Infarction

  NCT05336435· Herlev Hospital· Source

• Completed

  A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

  NCT05093933· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Eosinophil-guided Reduction of Inhaled Corticosteroids

  NCT04481555· Phase 4· Chronic Obstructive Pulmonary Disease Trial Network, Denmark· Source

• Completed

  Optimal Peripheral Nerve Block After Minimally Invasive Colon Surgery

  NCT04311099· Phase 4· Claus Anders Bertelsen, PhD, MD· Source

• Terminated

  Comparing Mortality for Low vs High Peripheral Oxygen Saturation in COPD-patients With Acute Exacerbation

  NCT04223050· Phase 4· Esbjerg Hospital - University Hospital of Southern Denmark· Source

• Completed

  Quality of Life the Danish Multiple Myeloma Patients

  NCT02892383· Odense University Hospital· Source